Data Foundry

Medical device recalls 2026

Atellica CH Enzymatic Hemoglobin A1c — Class II medical device recall Z-2703-2026

Ongoing recall by Siemens Healthcare Diagnostics, Inc., reported 2026-07-15, distributed nationwide. The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyze

Recall numberZ-2703-2026
Product typeMedical device
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmSiemens Healthcare Diagnostics, Inc., Tarrytown, NY, United States
Recall initiated2026-06-08
Classified2026-07-08
Reported by FDA2026-07-15
DistributedNationwide (US)
Countries outside the USAE, AR, AT, AU, BD, BG, BO, BR, BS, CA, CH, CL, CN, CO, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GR, HK, HR, ID, IL, IN, IT, JO, JP, KE, KR, KW, LB, LT, LV, MX, MY, NL, NO, NZ, OM, PK, PL, PT, PY, QA, RO, RS, SG, SI, SK, SV, TH, TR, UY, VN, ZA
Quantity24,077 units
Reason classespotency
UPC / GTIN / UDI-DI00630414220505

Product

Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536.

Reason for recall

The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyzer which could cause falsely depressed or falsely elevated HbA1c patient results.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/Z-2703-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.